CStone Pharmaceuticals’ Sugemalimab Gains Key ESMO Guideline Inclusion

CStone Pharmaceuticals ( (HK:2616) ) just unveiled an announcement.

CStone Pharmaceuticals announced that its product, sugemalimab (Cejemly®), has been included in the European Society for Medical Oncology (ESMO) guidelines as a recommended first-line combination therapy for both squamous and non-squamous NSCLC. This significant inclusion underscores sugemalimab’s clinical benefits, as evidenced by the Phase III GEMSTONE-302 trial, and supports CStone’s global market expansion efforts. The company is actively pursuing strategic partnerships to further extend market access in Western Europe, Southeast Asia, and Canada.

More about CStone Pharmaceuticals

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies. The company specializes in antibody-based drugs, with a key focus on the treatment of cancer, including non-small-cell lung cancer (NSCLC).

YTD Price Performance: 2.61%

Average Trading Volume: 2,196,431

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$2.98B

For detailed information about 2616 stock, go to TipRanks’ Stock Analysis page.